NCT03899285View on ClinicalTrials.gov

Citalopram Titration in Early Non-responder Patients With Major Depressive Disorders

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 8, 2018

Primary Completion Date

December 8, 2018

Study Completion Date

December 8, 2018

Conditions
Major Depressive Disorder
Interventions
DRUG

Citalopram 20mg or 40 mg (phase 2)

For non-responders, a randomisation 1:1 was chosen. The group A will receive 40 mg and the group B will receive 20 mg once daily of citalopram for 14 days.

Trial Locations (1)

H1T 2M4

GMF-U Maisonneuve-Rosemont hospital, Montreal East

All Listed Sponsors
lead

Ciusss de L'Est de l'Île de Montréal

OTHER

NCT03899285 - Citalopram Titration in Early Non-responder Patients With Major Depressive Disorders | Biotech Hunter | Biotech Hunter